← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Press Releases
Date | Press release |
---|---|
2025-03-24 11:48:00 | Singlera Genomics Presented Non-invasive Testicular Toxicity Detection With Astellas At 2025 Sot Meeting San diego, march 24, 2025 (globe newswire) -- singlera genomics presented results showing a refined approach to detect drug-induced testicular toxicity using singlera’s cell-free dna methylation technology with astellas during the sot 2025 annual meeting. |
2025-02-27 10:00:00 | Astellas And Mbc Biolabs Announce The Sixth Annual Astellas Future Innovator Prize Awardees win a year of access to a prestigious life-science incubator in san francisco and to astellas expertise to further their research award helps biotech start-ups accelerate early drug discovery and research efforts northbrook, ill. , feb. 27, 2025 /prnewswire/ -- astellas pharma u.s. inc. (head of commercial: mike petroutsas, \"astellas\"), and mbc biolabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the astellas future innovator prize. |
2025-02-12 18:32:00 | U.s. Fda Approves Expanded Label For Astellas’ Izervay™ (avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy Izervay dosing approved beyond 12 months tokyo , feb. 12, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, \"astellas\") today announced the u.s. food and drug administration (fda) approved expanded u.s. prescribing information for izervay™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd). as a result, izervay is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing ga. |
2025-02-05 03:59:00 | Astellas Submits New Drug Application For Conditional Approval Of Avacincaptad Pegol For Geographic Atrophy In Japan - ministry of health, labour and welfare to evaluate acp as potential first and only treatment for patients with geographic atrophy (ga) secondary to age-related macular degeneration (amd) in japan - tokyo , feb. 5, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503) (president and ceo: naoki okamura, \"astellas\") today announced the submission of a new drug application (nda) to japan’s ministry of health, labour and welfare (mhlw) for conditional approval of avacincaptad pegol intravitreal solution (acp), a synthetic aptamer that inhibits the complement c5 protein, for the treatment of ga secondary to amd. if approved, acp has the potential to become the first and only ga treatment available in japan. |
2025-02-04 01:30:00 | Astellas Makes Announcement About Management Structure Tokyo , feb. 4, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, \"astellas\") today announced that the following changes to its management structure effective april 1, 2025. regarding the change s in management structure astellas aims to create and deliver \"value\" for patients. |
2024-12-25 20:30:00 |
|
2024-12-05 08:49:00 |
|
2024-11-20 13:00:00 |
|
2024-10-10 03:00:00 |
|
2024-10-08 09:27:00 |
|
2024-10-01 16:24:00 |
|
2024-09-20 09:17:00 |
|
2024-09-18 19:30:00 |
|
2024-09-11 02:00:00 |
|
2024-09-05 10:00:00 |
|
